Home » A phase 1, open label, non-comparative, monocenter study to evaluate the safety and the ability of UCART19 to induce molecular remission in paediatric patients with relapsed /refractory B acute lymphoblastic leukaemia – UCART19_PALL » CL1-068587-001-laysummary-2021.09.09